SLC12A2 and stroke disorder: Blocking of the SPAK–NKCC1 pathway with the novel SPAK inhibitor ZT-1a or NKCC1 inhibitor bumetanide protected ChP against the stroke-induced damage and oxidative stress-induced apoptosis.